teins. Patients with mutations in these 2 genes are phenotypically indistinguishable with short stature, genu valgum, short ribs, polydactyly, dysplasia of the teeth and nails as well as normal hearing [Ruiz-Perez et al., 2003] . Congenital atrial septal defects are observed in 50-60% of the patients [Digilio et al., 1999] . Mutations in EVC and EVC2 each account for approximately half of Ellisvan Creveld syndrome diagnoses, and it is assumed that any additional unidentified genes comprise a small proportion of the overall diagnostic rate [Ruiz-Perez and Goodship, 2009] . Ellis-van Creveld syndrome has a prevalence in the general population of approximately 7 per 1,000,000, with equal occurrence in males and females [Stoll et al., 1989] . Interestingly, Ellis-van Creveld syndrome is much more frequent in the Old Order Amish in Lancaster County, Pennsylvania, with a 1 in 200 incidence rate due to a founder mutation [Ide et al., 1996] .
Mutations in COL11A2 (OMIM 120290) in chromosome 6p21.32 are associated with a number of different conditions that include autosomal dominant (DFNA13, OMIM 601868) or recessive (DFNB53, OMIM 609706) nonsyndromic hearing loss as well as Stickler syndrome (OMIM 184840), otospondylmegaepiphyseal dysplasia (OMIM 215150), fibrochondrogenesis (OMIM 614524), and Weissenbacher-Zweymuller syndrome (OMIM 277610) that are characterized by significantly overlapping skeletal abnormalities, hearing loss, and distinctive facial features. Hereditary hearing loss is the most common sensorineural disorder with a prevalence of roughly 1-2 per 1,000 newborns [Morton and Nance, 2006] . COL11A2 encodes collagen type XI that is one of 4 collagen proteins in the tectorial membrane. This acellular gelatinous sheetlike structure in the inner ear is important for frequencyspecific mechanical transmission and sound wave propagation to the inner hair cells [Masaki et al., 2009] .
Next-generation sequencing (NGS) panels provide informative molecular genetic data about genes associated with a disease of interest. Gene panels are particularly advantageous for permitting customized content, deeper sequencing coverage in GC-rich regions compared to whole-exome sequencing, and rapid clinical interpretation without risk of incidental or secondary findings [Saudi Mendeliome Group, 2015; Falardeau et al., 2016] . A customized skeletal dysplasia (SKD) gene panel containing several hundred genes can provide informative diagnostic results about other phenotypes on the basis that many of the genes underlying SKD are also allelic with other disorders that involve deficits in non-skeletal organ systems. Such a panel also holds the potential for a "dual diagnosis" in patients. This involves the identification of an underlying molecular genetic cause for 2 separate diseases. Patients with 2 distinct disease phenotypes typically appear with a blended phenotype which may present as a novel syndrome to a clinician [Yang et al., 2013] . Additionally, patients with a dual diagnosis may mistakenly be presumed as manifesting an expanded phenotype of an already characterized disorder [Posey et al., 2017] .
In this study, NGS gene panel sequencing and analysis ensued in a proband with consanguineous parents of Iranian descent who presented with atypical suspected Ellisvan Creveld syndrome that included short stature, polydactyly, nail hypoplasia, and hearing loss. Molecular genetics analysis showed segregation of homozygous nonsense and frameshift mutations in the genes EVC2 and COL11A2 , respectively. This study provides an example of multilocus variations aggregating in a single proband and supports consideration of dual molecular diagnoses in a proband with atypical disease symptoms.
Clinical Report
The female proband (VI:4) was born after a normal gestation to healthy parents. She is one of 3 offspring from 2 first-cousin parents of Iranian descent ( Fig. 1 A) . Her family has a history of both Ellis-van Creveld syndrome and nonsyndromic hearing loss. Pedigree with hand and foot appearance of the proband with dual EVC2 and COL11A2 molecular diagnoses. A A 6-generation pedigree of the proband (VI:4, arrow) shows individuals with Ellis-van Creveld syndrome and nonsyndromic hearing loss, who are represented by a top-and bottom-shaded symbol, respectively. Ellis-van Creveld syndrome was diagnosed in individuals II:1, III:1, V:7, and VI:5. Nonsyndromic hearing loss was reported in individuals III:2, V:8, and VI:1. The proband (VI:4), represented by a black circle, has both phenotypic features. B Sequence chromatograms showing the homozygous, heterozygous, and wildtype images for both COL11A2 and EVC2 variant regions. A control individual has been included for visualization of the COL11A2 wild-type allele. C The lower limbs of the proband showing asymmetry, short feet, pes planus, broad toes, bilateral metatarsal shortening (T2-T4), and micronychia. Right dorsum ( D ), left dorsum ( E ), and right plantar ( F ) images of the proband's hands after surgical correction of the bilateral postaxial hexadactyly showing hypoplasia of the fingers (F2-F4), generalized brachytelephalangy, and generalized micronychia. were diagnosed with Ellis-van Creveld syndrome and both died at the age of 3 years. In addition to this syndrome, her brother also presented with agenesis of the stomach. Individuals II:1 and III:1 were diagnosed with Ellis-van Creveld syndrome and individuals III:2 and VI:1 were diagnosed with nonsyndromic hearing loss. None of these individuals have a blended phenotype with overlapping features. The proband was 23 years old when she was referred for genetic counseling ( Fig. 1 A) . She showed a disproportionate shortlimb dwarfism with distalward shortening of extremities. Her body measurement of 137 cm ( Z -score of -4) was in the 50th percentile of the adapted growth tables for patients with Ellis-van Creveld syndrome [Verbeek et al., 2011] . She showed a congenital absence of mandibular central and lateral incisors, postaxial hexadactyly of fingers, hypoplasia of the F2-F4 digits, generalized brachytelephalangy and micronychia, lower limb asymmetry, generalized broad toes, bilateral metatarsal T2-T4 shortening, pes planus, and bilateral increased sole creases ( Fig. 1 C-F) [Biesecker et al., 2009] . No cardiac defects were identified. She experienced irregular menstrual cycles and secondary amenorrhea. Vision and intelligence were normal at examination.
Plain radiographs revealed postaxial hexadactyly without fusion of metacarpals or fingers ( Fig. 2 A) , distalward shortening of the tubular bones with short broad middle phalanges and hypoplastic distal phalanges ( Fig. 2 B) , cone-shaped epiphyses of the middle and distal phalanges, the classical wide and slanted proximal tibia metaphyses and the left proximal short fibula were also present ( Fig. 2 B-D) . The shortening of the tubular bones and mild irregularities of the proximal femoral metaphyses were also evident [Spranger et al., 2002] .
Bilateral sensorineural hearing loss was diagnosed postlingually and is described as progressive. Audiogram thresholds indicate a moderate hearing loss (data not shown).
Materials and Methods

Next-Generation Sequencing
Genomic DNA from individuals VI:4 (proband), VI:3 (unaffected sister), V:5 (mother), and V:6 (father) ( Fig. 1 A) was prepared from whole blood using a standard salt extraction method. The proband was analyzed using a customized SKD NGS panel, which consists of 373 genes that have been curated for SKD-related phenotypes (gene list is available upon request). Library preparation was performed using the SureSelect XT Custom kit (Agilent Technology, Santa Clara, CA, USA) and NEBNextUltra DNA Library Prep kit (New England BioLabs, Ipswich, MA, USA) according to manufacturer's protocols. 1 μg of genomic DNA was fragmented and 150-500-bp size products were selected for subsequent adapter and barcode labeling. RNA-based baits were hybridized with labeled DNA, and target genomic regions were enriched using the Agencourt AMPure XP system (Beckman Coulter, Brea, CA, USA). Libraries were quality controlled on the Agilent 2200 Tape Station (Agilent Technology). 150-bp pairedend sequencing was performed on an Illumina MiSeq sequencer using MiSeq v2 chemistry (Illumina, San Diego, CA, USA).
Bioinformatics Analysis
Sequencing data was de-multiplexed and FASTQ files generated by CASAVA v1.8.2 (Illumina). Sequencing reads were assembled and aligned to the human reference sequence (GRCh37/ hg19), and variants were called using an in-house modified GATK pipeline. The raw VCF file was imported to Cartagenia Bench Lab NGS software (Agilent Technology) for variant filtering. Variants from the filter chain were analyzed using Alamut 2.7.2 software (Interactive Biosoftware, Rouen, France). Allele frequencies were acquired from ExAC and gnomAD [Lek et al., 2016] as well as the Greater Middle Eastern database [Scott et al., 2016] . The Deafness Variation Database was used to assess variants in COL11A2 [Shearer et al., 2014] . 
Sanger Sequencing
Bidirectional Sanger sequencing was performed to confirm positive findings in the proband and family members using BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) on a 3730xl DNA Analyzer (Applied Biosystems). EVC2 (GenBank: NM_147127) exon 15 was amplified using standard PCR cycling conditions and a forward (5 ′ -TTCTG-TAATCGGCCACTGAC AGG-3 ′ ) and reverse (5 ′ -ATGGATAT-GAGGAATGAGCTTTGC-3 ′ ; 338 bp) primer pair. A 214-bp region of exon 8 in COL11A2 (GenBank: NM_080680) (forward: 5 ′ -ATAGGTGTAATCGTA GGGCCC-3 ′ and reverse primer: 5 ′ -AACCTTGGAATCCTTT GGGC-3 ′ ) employed standard cycling conditions. Primers were designed using Primer3 [Untergasser et al., 2012] . Sanger sequencing data were analyzed by Sequencher 5.3 software (Gene Codes, Ann Arbor, MI, USA).
Results
Genetic Investigations
Conventional chromosome banding analysis of the proband revealed a normal 46,XX karyotype. NGS gene panel sequencing yielded high-quality data with an average of 479x coverage. A total of 2,276 variant calls were made by the pipeline and 2,123 passed quality control. After excluding intergenic and deep intronic variants, 730 variants in the coding region or intron-exon boundaries were analyzed through a multi-tier filter chain ( Fig.  3 ) . Subsequently, 2 homozygous pathogenic variants remained: a cytosine insertion resulting in a frameshift and a premature stop codon (c.966dup; p.Thr323His fs * 19) in exon 8 of the gene COL11A2 as well as a nonsense (c.2653C>T; p.Arg885 * ) mutation in exon 15 of the gene EVC2 that were both predicted to be disease causing by MutationTaster [Schwarz et al., 2010] ( Table 1 ) . The COL11A2 c.966dup mutation is not archived in ClinVar [Landrum et al., 2016] , HGMD [Stenson et al., 2017] , or LOVD [Fokkema et al., 2011] ; however, it has been recently identified in 2 Iranian families and is annotated in the Deafness Variation Database as a pathogenic autosomal recessive nonsyndromic hearing loss mutation ( Table 2 ) [Shearer et al., 2014; Sloan-Heggen et al., 2015] . The EVC2 c.2653C>T mutation is described as pathogenic in ClinVar and HGMD and is associated with chondroectodermal dysplasia and Ellis-van Creveld syndrome, respectively. No other deleterious homozygous or com- 10 pound heterozygous mutations were identified. Segregation analysis was performed in 4 family members and confirmed both homozygous mutations ( Fig. 1 B) . Sanger sequencing showed that both parents (V:5 and V:6) were heterozygous carriers for both EVC2 and COL11A2 mutations, and the sister (VI:3) was a heterozygous carrier for the COL11A2 mutation but wild type at the EVC2 mutation position.
Discussion
Ellis-van Creveld syndrome is usually diagnosed by pathogenic biallelic mutations in either EVC or EVC2. The homozygous nonsense mutation (c.2653C>T; p. Arg885 * ) identified in EVC2 provided a molecular diagnosis of the suspected Ellis-van Creveld syndrome, the more prominent phenotype in the proband, but did not provide a molecular basis for hearing loss. The blending of 2 distinct phenotypes prompted an in-depth data analysis that led to a dual molecular diagnosis by identifying a homozygous COL11A2 single nucleotide duplication that likely explained the 2 features present as isolated symptoms in various other family members ( Fig. 1 A) .
Genotype-phenotype correlations have not been performed for EVC2 ; however, the c.2653C>T (p.Arg885 * ) mutation has been previously described in 3 patients ( Table 3 ). Interestingly, the 2 patients with compound heterozygous mutations exhibited differing clinical severities. The initial publication identifying the c.2653C>T mutation described this in a compound heterozygous state with an IVS5-2A>G change in a female Chinese patient [Shen et al., 2011 ]. This patient was described with a mild syndrome that included postaxial polydac- tyly, nail dysplasia, tooth abnormalities, and mild short stature. Cardiac defects and narrow thorax were absent. In contrast, a Japanese patient with compound heterozygous nonsense mutations (c.2653C>T; p.Arg885 * and c.1814C>A; p.Ser605 * ) had a distinctly severe form of Ellis-van Creveld syndrome that included a partial atrioventricular septal defect, prominent developmental delay, and chronic intestinal malfunction requiring surgical resection [Iwakura et al., 2016] . A Lebanese patient with the same homozygous c.2653C>T (p.Arg885 * ) mutation as the proband we describe displayed a mild syndromic presentation [Valencia et al., 2015] . The phenotype in our patient is comparatively mild. It remains unknown whether the deaths in individuals V:7 and VI:5 can be directly attributed to the syndrome. There are presently 67 mutations reported in EVC2 that constitute 27 nonsense, 14 small deletions, 7 small insertions/duplications, 6 each for gross deletions, missense, and splicing mutations as well as 1 gross insertion/ duplication (HGMD, version 2017.1). The majority of these mutations encode a loss of function, which is supported by an absence of homozygous loss-of-function alleles in the ExAC, the Greater Middle Eastern, or gnomAD databases ( Table 1 ) .
Although nonsyndromic sensorineural hearing loss and a phenotypic spectrum of syndromes involving skeletal malformation and hearing loss that include Stickler and Weissenbacher-Zweymuller syndromes, otospondylmegaepiphyseal dysplasia, and fibrochondrogenesis are caused by allelic mutations in COL11A2 ( Fig. 4 A, B) , the c.966dup mutation appears restricted to autosomal recessive nonsyndromic sensorineural hearing loss and was described in 2 Iranian families of Fars and Turk ethnicities with affected individuals indicating prelingual, profound autosomal recessive nonsyndromic hearing loss ( Table 2 ) [Sloan-Heggen et al., 2015] . As the family we present is of Iranian descent, it is tempting to speculate a founder effect considering that hearing loss due to homozygosity of this allele has only been reported in Iranians to date. In the presented family, 3 individuals from the paternal lineage have isolated nonsyndromic hearing loss. However, we cannot exclude that the hearing loss in these family members is due to another locus since these individuals were unavailable for molecular genetic testing. Six previously published families from Iran, Japan, Tunisia, and Turkey have been identified as segregating autosomal recessive COL11A2 alleles causing nonsyndromic hearing loss [Chen et al., 2005; Miyagawa et al., 2013; Chakchouk et al., 2015; Sloan-Heggen et al., 2015] . Affected members in these families were described with congenital or prelingual, severe-to-profound sensorineural hearing loss ( Table 2 ). Only one of the families showed short stature with no other orthopedic abnormalities present [Chakchouk et al., 2015] . We describe the first patient with moderate, progressive, postlingual hearing loss caused by a homozygous autosomal recessive CO-L11A2 allele ( Table 2 ). The limited number of patients described in the literature with autosomal recessive deafness manifest prelingual, profound hearing loss.
The Gly-X-Y triplet repeat motif, wherein X and Y are the ring amino acids proline and hydroxyproline, is required to stabilize the triple-helix repeat domain in COL11A2 [Yoneda et al., 1999] . There are currently 5 mutations recognized as causing recessive nonsyndromic hearing loss ( Table 2 ) . Two of the 5 mutations (c.966dup; p.Thr323Hisfs * 19 and c.109G>T; p.Ala37Ser) do not disrupt the Gly-X-Y motif, whereas 3 mutations (c.1861C>A; p.Pro621Thr, c.2002C>T; p.Pro668Ser, and c.2662C>T; p.Pro888Ser) reside in regions of the protein that alter the Gly-X-Y repeat, likely impacting triple-helix stability ( Fig. 4 A) . Further reports are required for an in-depth genotype-phenotype correlation of protein domain disruption on hearing loss outcome, including the potential outcome of the N-and C-terminal, laminin G and fibrillary collagen domains, respectively. Interestingly, the c.966dup mutation is the only identified mutation with a premature protein truncation that is linked to nonsyndromic hearing loss to date, expanding the present understanding that insertions, deletions, nonsense, or Gly-X-Y triplet repeat motif altering mutations are linked to severe 13 multisystemic phenotypes, such as otospondylmegaepiphyseal dysplasia [Haller et al., 2016] , and missense mutations are responsible for nonsyndromic deafness [Tokgöz-Yılmaz et al., 2011] . NGS panels with extensive gene content provide an opportunity to apply a genotype-first approach to identify a clinically atypical patient who may otherwise be regarded as manifesting a phenotypic expansion of a mendelian disorder. It is important to emphasize that the field is still witness to rapid gene identification, making the efficiency of molecular diagnosis of multiple disorders imperfect, especially within the context of gene panels that are limited to disease-specific gene content. However, several studies have provided promising insight with current knowledge and have shown that multilocus genomic variation occurs in approximately 4-5% of the patients referred for genetic testing using whole-exome sequencing [Balci et al., 2017; Posey et al., 2017] . The largest retrospective study to date included 7,374 diagnostic patients, including 2,076 (28.1%) patients achieving a diagnosis. Among those with a diagnosis, 97 patients had a molecular diagnosis involving 2 loci, 3 patients had a molecular diagnosis involving 3 loci, and 1 patient encountered 4 molecular diagnoses, accounting for a combined 101 patients with a diagnosis involving 2 or more loci (4.9%). Focusing on the nonsyndromic hearing loss genetic results from this study, 4 of the 97 patients (4.1%) receiving a dual diagnosis had variants in genes responsible for nonsyndromic hearing loss in combination with an additional gene harboring pathogenic variants. This included one patient with pathogenic mutations in both ACTG1 and WFS1 that underlie autosomal dominant and recessive forms of hearing loss, respectively [Posey et al., 2017] .
Several studies have concluded that parental consanguinity and multisystem disease are 2 essential factors increasing the likelihood of a dual molecular diagnosis [Balci et al., 2017] . In parts of the world where consanguinity is prevalent, it is not uncommon to observe an increase in autosomal recessive disorders in offspring due to homozygous inheritance of parental carrier mutations that are identical by descent. With respect to nonsyndromic hearing loss, an extremely heterogeneous disorder, a previous study has estimated that nonconsanguineous normal hearing individuals carry an average of approximately 1.4 deleterious variants, with some individuals carrying as many as 3 deleterious variants [Vona et al., 2014] . Approximately 70% of nonsyndromic hearing loss is transmitted as an autosomal recessive disorder, making the inheritance of recessively inherited hearing loss in a proband from a consanguineous union not unforeseen.
An accurate molecular diagnosis is critical for genetic counseling in this family. A mixture of different phenotypes and coexistence of multiple disease-causing genotypes in the proband makes counseling even more challenging. Since clinical symptoms were segregating in different pedigree branches and complex consanguinity was observed, counseling for each of the at-risk family members has to consider both disease conditions based on their mutation status, their relationship to the proband, and their own consanguinity level. In addition, carrier status of additional autosomal recessive diseases has been identified in the proband through NGS (data not shown). These may not explain the disease etiology of the proband; however, they may bring an extra layer of complexity to genetic counseling because all intrafamily members will have an increased risk of having offspring with these recessive conditions due to consanguinity. At this point, comprehensive genetic counseling and additional genetic testing may be necessary for all family members for future family planning.
In light of the uncovered findings, there are 2 possible scenarios that merit discussion. Firstly, if investigators had solely noted the COL11A2 variant, with its association with hearing loss and overlapping skeletal malformation, this may have prematurely resulted in a diagnosis if further analysis had not ensued that uncovered the EVC2 nonsense mutations. An alternative sequence of events could have involved the discovery of the EVC2 nonsense mutation without further analysis, which may lead investigators to believe that hearing loss is a novel feature of Ellis-van Creveld syndrome. Both of these outcomes would have led to an incomplete result.
In summary, patients with multiple diagnoses are under-recognized in molecular diagnostic settings. NGS analysis may reveal more than one distinct mendelian disease leading to a dual diagnosis. An initial molecular diagnosis may be incomplete when an apparently new clinical phenotype or a phenotypic expansion of a single disease is assumed. Our data challenge the notion that a diagnostic investigation is not necessarily complete after a single genetic mutation has been identified.
